B Ruiter1,2, S U Patil1,2,3, W G Shreffler1,2,3. 1. Center for Immunology & Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA. 2. Harvard Medical School, Boston, MA, USA. 3. Food Allergy Center, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Retinoic acid (RA), the main biologically active metabolite of vitamin A, is known to promote gut homing of lymphocytes, as well as various regulatory and effector immune responses. In contrast, the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3), is predominantly immunosuppressive. Little is known about the direct effects of these vitamins on the recently identified innate lymphoid cells (ILCs). OBJECTIVE: We sought to characterize the effects of RA and 1,25D3 on human ILCs. METHODS: Peripheral blood mononuclear cells were isolated from 27 non-selected blood donor buffy coats, and ILCs were sorted by FACS. ILC1, ILC2, and ILC3 cells were cultured for 5 days with RA, 1,25D3, and various cytokines known to activate ILCs (IL-2, IL-7, IL-12, thymic stromal lymphopoietin (TSLP), IL-25, and IL-33). Cytokines produced by ILCs were measured in culture supernatants, and surface receptor expression was analysed by flow cytometry. RESULTS: Retinoic acid acted synergistically with IL-2 and other activating cytokines to induce expression of the gut-homing integrin α4β7 in ILCs, as well as production of IL-5 and IL-13 in ILC2 cells, and IFN-γ in ILC1 and ILC3 cells. Expression of integrin α4β7 and cytokine production in ILCs stimulated with RA + IL-2 was increased at least fourfold as compared to ILCs cultured with RA or IL-2 alone. In contrast, RA completely inhibited the IL-2-induced expression of cutaneous lymphocyte antigen (CLA) in ILCs. Moreover, addition of 1,25D3 to ILCs cultured with RA + IL-2 inhibited cytokine production and expression of integrin α4β7 by at least 30%. CONCLUSIONS: Retinoic acid and 1,25D3 have antagonistic effects on the expression of effector cytokines and gut-homing integrin by human ILCs. The balance between these vitamins may be an important factor in the functioning of ILCs and the diseases in which ILCs are implicated, such as allergic inflammation.
BACKGROUND:Retinoic acid (RA), the main biologically active metabolite of vitamin A, is known to promote gut homing of lymphocytes, as well as various regulatory and effector immune responses. In contrast, the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3), is predominantly immunosuppressive. Little is known about the direct effects of these vitamins on the recently identified innate lymphoid cells (ILCs). OBJECTIVE: We sought to characterize the effects of RA and 1,25D3 on human ILCs. METHODS: Peripheral blood mononuclear cells were isolated from 27 non-selected blood donor buffy coats, and ILCs were sorted by FACS. ILC1, ILC2, and ILC3 cells were cultured for 5 days with RA, 1,25D3, and various cytokines known to activate ILCs (IL-2, IL-7, IL-12, thymic stromal lymphopoietin (TSLP), IL-25, and IL-33). Cytokines produced by ILCs were measured in culture supernatants, and surface receptor expression was analysed by flow cytometry. RESULTS:Retinoic acid acted synergistically with IL-2 and other activating cytokines to induce expression of the gut-homing integrin α4β7 in ILCs, as well as production of IL-5 and IL-13 in ILC2 cells, and IFN-γ in ILC1 and ILC3 cells. Expression of integrin α4β7 and cytokine production in ILCs stimulated with RA + IL-2 was increased at least fourfold as compared to ILCs cultured with RA or IL-2 alone. In contrast, RA completely inhibited the IL-2-induced expression of cutaneous lymphocyte antigen (CLA) in ILCs. Moreover, addition of 1,25D3 to ILCs cultured with RA + IL-2 inhibited cytokine production and expression of integrin α4β7 by at least 30%. CONCLUSIONS:Retinoic acid and 1,25D3 have antagonistic effects on the expression of effector cytokines and gut-homing integrin by human ILCs. The balance between these vitamins may be an important factor in the functioning of ILCs and the diseases in which ILCs are implicated, such as allergic inflammation.
Authors: S P Spencer; C Wilhelm; Q Yang; J A Hall; N Bouladoux; A Boyd; T B Nutman; J F Urban; J Wang; T R Ramalingam; A Bhandoola; T A Wynn; Y Belkaid Journal: Science Date: 2014-01-24 Impact factor: 47.728
Authors: Jason A Hall; Jennifer L Cannons; John R Grainger; Liliane M Dos Santos; Timothy W Hand; Shruti Naik; Elizabeth A Wohlfert; David B Chou; Guillaume Oldenhove; Melody Robinson; Michael E Grigg; Robin Kastenmayer; Pamela L Schwartzberg; Yasmine Belkaid Journal: Immunity Date: 2011-03-25 Impact factor: 31.745
Authors: Zoë Urry; Emma S Chambers; Emmanuel Xystrakis; Sarah Dimeloe; David F Richards; Leona Gabryšová; Jillian Christensen; Atul Gupta; Sejal Saglani; Andrew Bush; Anne O'Garra; Zarin Brown; Catherine M Hawrylowicz Journal: Eur J Immunol Date: 2012-08-20 Impact factor: 5.532
Authors: Lisa A Mielke; Sarah A Jones; Mathilde Raverdeau; Rowan Higgs; Anna Stefanska; Joanna R Groom; Alicja Misiak; Lara S Dungan; Caroline E Sutton; Gundula Streubel; Adrian P Bracken; Kingston H G Mills Journal: J Exp Med Date: 2013-05-20 Impact factor: 14.307
Authors: Mara J Broadhurst; Jacqueline M Leung; K C Lim; Natasha M Girgis; Uma Mahesh Gundra; Padraic G Fallon; Mary Premenko-Lanier; James H McKerrow; Joseph M McCune; P'ng Loke Journal: PLoS Pathog Date: 2012-08-23 Impact factor: 6.823
Authors: Maryam Salimi; Jillian L Barlow; Sean P Saunders; Luzheng Xue; Danuta Gutowska-Owsiak; Xinwen Wang; Li-Chieh Huang; David Johnson; Seth T Scanlon; Andrew N J McKenzie; Padraic G Fallon; Graham S Ogg Journal: J Exp Med Date: 2013-12-09 Impact factor: 14.307
Authors: Maya R Karta; Peter S Rosenthal; Andrew Beppu; Christine Y Vuong; Marina Miller; Sudipta Das; Richard C Kurten; Taylor A Doherty; David H Broide Journal: J Allergy Clin Immunol Date: 2017-03-30 Impact factor: 10.793
Authors: Eunsoo Kim; Astrid Bonnegarde-Bernard; Stephen O Opiyo; Marisa R Joldrichsen; Zayed Attia; Brian H Ahmer; Estelle Cormet-Boyaka; Prosper N Boyaka Journal: Mucosal Immunol Date: 2021-09-09 Impact factor: 7.313